Dubai, UAE – Nomas Global Investments LLC‑S.P.C., a prominent investment firm based in the UAE and owned by H.H. Shaikh Mohammed Bin Sultan Bin Hamdan Al Nahyan, has announced a significant USD 175 million investment in Beaufond Plc. , marking a key milestone in the companies, “Strategic Partnership”.
As part of the deal, Nomas has acquired an equity stake in Beaufond, which continues to be valued at USD 4.36 billion. This move highlights the continued trust and confidence in Beaufond’s robust growth trajectory within the pharmaceutical, trading, and research sectors.
Strategic Growth and Future Outlook
The USD 175 million investment will enable Beaufond to enhance its Contract manufacturing capabilities, increase production efficiency, and meet rising global demand for medicines. Beaufond will also focus on its core areas of strength, including 3D-printed drugs, oncology treatments, and biopharmaceuticals, while expanding its reach in global markets such as Europe, Asia, and Africa.
“The strategic partnership between Nomas Global Investments and Beaufond is a testament to the power of collaboration in achieving sustainable, long-term growth,” said H.H. Shaikh Mohammed Bin Sultan Bin Hamdan Al Nahyan, founder and chairman of Nomas Global Investments. “We are excited to support Beaufond in its ongoing efforts to revolutionize the pharmaceutical industry, particularly in areas of cutting-edge drug development and manufacturing excellence.”
Beaufond’s CEO, Vikram Motwani, also commented on the investment: “Nomas’s significant financial commitment and long-term vision provide a solid foundation for Beaufond as we continue our expansion into key global markets. This partnership will play a crucial role in realizing our mission to make life-saving medicines more accessible to people around the world.”
Impact on UAE Economic Development
The partnership is expected to have a positive economic impact on the UAE, particularly in terms of job creation and the development of a highly skilled workforce in the pharmaceutical sector. The new manufacturing facility will be a cornerstone of Beaufond’s local operations and will help facilitate the UAE’s strategic goals to become a global hub for pharmaceutical innovation.
About Nomas Global Investments LLC‑S.P.C.
Nomas Global Investments LLC‑S.P.C. is a UAE-based investment firm specializing in strategic investments across diverse sectors, including renewable energy, trading, and pharmaceuticals. The firm is backed by H.H. Shaikh Mohammed Bin Sultan Bin Hamdan Al Nahyan, a prominent member of the Abu Dhabi royal family. Nomas focuses on long-term value creation through targeted investments and active partnership-building.
About Beaufond Plc
Beaufond Plc. is a multinational company based in the UAE, specializing in the pharmaceuticals, trading, and technology sectors. With operations spanning multiple continents, Beaufond is dedicated to improving healthcare outcomes through its innovations in drug manufacturing, advanced formulations, and pharmaceutical research. The company has a track record of successful product launches and global market expansion.
—
Contact Information
For Media Inquiries:
Nomas Global Investments LLC‑S.P.C.
Email: press@nomasglobal.com
Beaufond Plc
Email: media@admin
Phone: +971-4-5751343
Global Headquarters
Beaufond Plc #3502, Saeed Tower – 2, S.Z Road Near Financial Centre Metro Station, Dubai, United Arab Emirates
Contact Information
Tel: +971-4-575-1343 | Email: info@beaufond.com
Business Hours: Monday – Friday, 09:00 AM – 18:00 PM